Silver Book Fact

An increase in bone mineral density (BMD) testing and osteoporosis treatment was associated with a decrease in hip fracture incidence.

Jaglal S, Weller I, Mamdani M, et al. Population Trends in BMD Testing, Treatment, and Hip and Wrist Fracture Rates: Are the hip fracture projections wrong?. Arch Intern Med. 2005; 159(11): 1215-20. http://www.ncbi.nlm.nih.gov/pubmed/15883628

Reference

Title
Population Trends in BMD Testing, Treatment, and Hip and Wrist Fracture Rates: Are the hip fracture projections wrong?
Publication
Arch Intern Med
Publication Date
2005
Authors
Jaglal S, Weller I, Mamdani M, et al
Volume & Issue
Volume 159, Issue 11
Pages
1215-20
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • The Study of Osteoporotic Fractures, which began over 20 years ago, found that bone mineral density (BMD) of the hip is one of the best predictors of fracture for women,…  
  • Researchers are looking at the use of micro-computed tomography and magnetic resonance imaging to better understand the relationship between bone structure and fracture risk. Other tools are being evaluated for…  
  • Alendronate, a bisphosphonate, has been shown to reduce risk of hip fracture by around 53%, clinical vertebral fracture by 45%, and wrist fracture by 30%.  
  • Teriparatide, or human recombinant PTH, has been shown to increase vertebral bone mineral density (BMD) by 9% to 13%.  
  • Risedronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by around 5% and hip BMD by 2% to 3% in postmenopausal women with osteoporosis.